Table 2 Detailed results of the progression-free survival analysis.

Univariate analysis

Sex

0.926

Age at CAR-T

0.674

High age (> 60)

0.838

BMI

0.531

ECOG performance status

0.174

High ECOG status (2–3)

0.135

LDH

1.001 (1.000–1.002.000.002)

0.013*

Abnormal LDH (> 220)

0.198

High LDH (> 300)

2.181 (1.306–3.644)

0.003*

Stage III/IV at CAR-T

0.424

High IPI (> 2)

0.086

High NCCN-IPI (> 3)

0.150

IMPI risk

0.708

1-month CR (n = 51)

0.150

3-month CR (n = 66)

0.218 (0.103–0.464)

< 0.001*

Extranodal lymphomatous involvement

1.767 (1.050–2.976)

0.032*

SUVmax

1.023 (1.003–1.045)

0.026*

High SUVmax (> 17.5)

2.555 (1.455–4.488)

0.001*

SUVmean

0.095

High SUVmean (> 6.5)

1.824 (1.097–3.033)

0.020*

SUVpeak

1.027 (1.004–1.051)

0.019*

High SUVpeak (> 17)

2.469 (1.431–4.261)

0.001*

SUVmax-to-liver background

1.057 (1.016–1.100.016.100)

0.006*

High SUVmax-to-liver background (> 5)

3.474 (1.494–8.080)

0.004*

SUVmean-to-liver background

1.213 (1.027–1.432)

0.023*

High SUVmean-to-liver background (> 2.5)

2.777 (1.366–5.645)

0.005*

MTV

1.000 (1.000–1.001.000.001)

0.020*

High MTV (> 22)

3.996 (1.718–9.293)

0.001*

TLG

1.000 (1.000–1.000)

0.007*

High TLG (> 105)

7.511 (2.351–24.000.351.000)

< 0.001*

Dmax

1.001 (1.000–1.002.000.002)

0.002*

High Dmax (> 15)

2.900 (1.538–5.469)

0.001*

Standardized Dmax

1.002 (1.001–1.004)

0.002*

High standardized Dmax (> 8)

3.044 (1.581–5.860)

< 0.001*

SDmax (Spleen Dmax)

1.002 (1.001–1.003)

0.011*

High SDmax (> 23)

2.021 (1.025–3.987)

0.042*

Standardized SDmax

1.004 (1.001–1.006)

0.003*

High standardized SDmax (> 16)

1.916 (1.133–3.242)

0.015*

Multivariate analysis

High LDH

1.678 (1.000–2.820.000.820)

0.049*

Extranodal lymphomatous involvement

1.369 (0.806–2.325)

0.246

High SUVmax-to-liver background

1.121 (0.410–3.068)

0.823

High TLG

4.306 (1.001–18.520)

0.048*

High standardized Dmax

1.556 (0.768–3.156)

0.220